Terrance Mcguire Sells 83,817 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 83,817 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $0.54, for a total value of $45,261.18. Following the completion of the transaction, the director now directly owns 3,340,520 shares of the company’s stock, valued at approximately $1,803,880.80. This trade represents a 2.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The stock was sold at an average price of $0.42, for a total value of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

IVVD stock traded up $0.02 during trading on Thursday, hitting $0.53. 870,708 shares of the company traded hands, compared to its average volume of 667,876. Invivyd, Inc. has a 1 year low of $0.40 and a 1 year high of $5.20. The company has a market cap of $63.44 million, a PE ratio of -0.27 and a beta of 0.53. The stock’s 50-day simple moving average is $0.74 and its 200 day simple moving average is $0.99.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. HC Wainwright dropped their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $7.89.

Institutional Trading of Invivyd

Several institutional investors have recently modified their holdings of the stock. Duquesne Family Office LLC purchased a new position in shares of Invivyd in the second quarter valued at approximately $629,000. Acadian Asset Management LLC lifted its holdings in Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after purchasing an additional 474,301 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new stake in Invivyd during the 2nd quarter worth $86,000. Cubist Systematic Strategies LLC raised its position in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.